Previous 10 | Next 10 |
Ardelyx (ARDX -0.9%) has implemented a restructuring plan after the FDA turned down the approval of the company’s kidney disease therapy tenapanor in July. The plan expected to be complete in Q3 2021 will lead to a nearly 33% decline in the company’s workforce and a ~$17M d...
ARDX received a CRL for tenapanor. It does not look like there will be a short term resolution here. However, the company has cash, and a small pipeline, and some chance of ultimate approval of tenapanor. For further details see: Ardelyx: Is There Any Value Left After Th...
ERYTECH Pharma S.A. (NASDAQ:ERYP) +99%. Ardelyx (NASDAQ:ARDX) +14% on Q2 earnings Taoping (NASDAQ:TAOP) +12% signs strategic cooperation agreement with Shenzhen IntelStrat Technology Co., Ltd Atlassian Corporation Plc (NASDAQ:TEAM) +12%. LM Funding America (NASDAQ:LMFA) +...
Ardelyx (NASDAQ:ARDX) is trading ~14.0% higher in the pre-market despite its announcement of the complete response letter received from the FDA regarding the marketing application for tenapanor for the control of serum phosphorus in adults with chronic kidney disease on dialysi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the end of the workweek but we’ve got one more day of trading to get through before that weekend break. Let’s start it off with a breakdown of the biggest pre-market stock market movers for Friday....
The U.S. FDA has declined to approve Ardelyx's (NASDAQ:ARDX) tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. In the complete response letter, the health regulator characterized the magnitude of the treatment effect as "small ...
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Conference call and webcast to be held at 5:00 PM ET PR Newswire FREMONT, Calif. and WALTHA...
Shares of Ardelyx Inc. (NASDAQ:ARDX) traded today at $1.59, breaking its 52-week low. So far today approximately 9.5 million shares have been exchanged, as compared to an average 30-day volume of 10.1 million shares. Ardelyx Inc is a biotechnology company focused on the discovery, develo...
Shares of Ardelyx Inc. (NASDAQ:ARDX) traded at a new 52-week low today of $1.67. Approximately 9.5 million shares have changed hands today, as compared to an average 30-day volume of 1.6 million shares. Ardelyx Inc. share prices have moved between a 52-week high of $9.23 and the current ...
Ardelyx Inc. (NASDAQ:ARDX) traded at a new 52-week low today of $1.91. This new low was reached on above average trading volume as 9.5 million shares traded hands, while the average 30-day volume is approximately 1.6 million shares. Over the past year, Ardelyx Inc. has traded in a range ...
News, Short Squeeze, Breakout and More Instantly...
Why The Stock Market Is Down Today Why is the stock market down today? The final week of June and the second quarter has been jam-packed with economic data and inflation-related events. Fed Chair Jerome Powell recently said that the global economy has entered a “new world”...
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners PR Newswire HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from ...
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 PR Newswire WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a missio...